| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MECOM |
| Uniprot No | Q13465 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-169aa |
| 活性数据 | MRSKGRARKL ATNNECVYGN YPEIPLEEMP DADGVASTPS LNIQEPCSPA TSSEAFTPKE GSPYKAPIYI PDDIPIPAEF ELRESNMPGA GLGIWTKRKI EVGEKFGPYV GEQRSNLKDP SYGWEVHLPR SRRVSVHSWL YLGKRSSDVG IAFSQADVYM PGLQCAFLS |
| 分子量 | 138,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MECOM蛋白的模拟参考文献，内容基于该蛋白的常见研究方向归纳概括：
1. **文献名称**：*High-yield expression and purification of recombinant human MECOM protein in HEK293 cells*
**作者**：Zhang L., et al.
**摘要**：本研究开发了一种基于HEK293细胞的高效重组人MECOM蛋白表达系统，优化了纯化条件，并通过质谱和免疫印迹验证了蛋白的正确折叠及功能活性，为后续功能研究提供了可靠工具。
2. **文献名称**：*MECOM/EVI1 modulates TGF-β signaling in leukemia through interaction with Smad proteins*
**作者**：Thompson R.B., et al.
**摘要**：研究揭示了重组人MECOM蛋白在白血病细胞中通过直接结合Smad蛋白抑制TGF-β信号通路，RNA干扰敲低MECOM后显著促进癌细胞凋亡，表明其在白血病发生中的关键调控作用。
3. **文献名称**：*Structural analysis of the zinc finger domains in human MECOM protein*
**作者**：Kurokawa M., et al.
**摘要**：利用X射线晶体学解析了重组人MECOM蛋白的锌指结构域三维结构，揭示了其与DNA靶序列结合的关键位点，突变实验验证了特定氨基酸残基对基因调控功能的影响。
4. **文献名称**：*Recombinant MECOM protein suppresses tumor growth in glioblastoma mouse models*
**作者**：Gupta S., et al.
**摘要**：实验证明通过腺病毒递送的重组人MECOM蛋白可抑制胶质母细胞瘤模型的肿瘤生长，机制涉及下调致癌基因c-Myc表达，提示其作为潜在治疗分子的价值。
---
注：以上文献为模拟概括，实际研究需参考具体发表的论文。如需真实文献，建议通过PubMed或Google Scholar搜索关键词“recombinant human MECOM/EVI1 protein”。
The recombinant human MECOM protein, derived from the MDS1 and EVI1 complex locus (MECOM) gene, encodes a zinc finger transcription factor critical for hematopoietic development, cell proliferation, and differentiation. Initially identified through its association with retroviral-induced myeloid tumors (as EVI1), MECOM regulates gene expression by binding DNA via conserved C2H2 zinc finger domains. Dysregulation of MECOM is linked to aggressive leukemias, myelodysplastic syndromes, and solid tumors, where its overexpression often correlates with poor prognosis and chemoresistance. Recombinant MECOM is typically produced in Escherichia coli or mammalian expression systems, enabling studies on its molecular mechanisms in oncogenesis and normal development. Researchers employ it to dissect interactions with chromatin modifiers (e.g., histone deacetylases) and signaling pathways (e.g., TGF-β), as well as its role in maintaining stem cell pluripotency. The purified protein also aids in structural analyses, drug discovery targeting MECOM-driven malignancies, and functional assays exploring its dual role as an oncogene or tumor suppressor depending on cellular context. Its production supports translational research aimed at therapeutic interventions for MECOM-associated diseases.
×
